{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T22:35:22Z","timestamp":1795300522419,"version":"4.10.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Blood lipids and metabolites are markers of current health and future disease risk. Here, we describe plasma nuclear magnetic resonance (NMR) biomarker data for 118,461 participants in the UK Biobank. The biomarkers cover 249 measures of lipoprotein lipids, fatty acids, and small molecules such as amino acids, ketones, and glycolysis metabolites. We provide an atlas of associations of these biomarkers to prevalence, incidence, and mortality of over 700 common diseases (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/nightingalehealth.com\/atlas\">nightingalehealth.com\/atlas<\/jats:ext-link>\n                    ). The results reveal a plethora of biomarker associations, including susceptibility to infectious diseases and risk of various cancers, joint disorders, and mental health outcomes, indicating that abundant circulating lipids and metabolites are risk markers beyond cardiometabolic diseases. Clustering analyses indicate similar biomarker association patterns across different disease types, suggesting latent systemic connectivity in the susceptibility to a diverse set of diseases. This work highlights the value of NMR based metabolic biomarker profiling in large biobanks for public health research and translation.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-36231-7","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T13:06:18Z","timestamp":1675429578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":569,"title":["Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4282-0248","authenticated-orcid":false,"given":"Heli","family":"Julkunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cicho\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri","family":"Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Nybo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtteri","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Nokso-Koivisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-107X","authenticated-orcid":false,"given":"Kati","family":"Kristiansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Perola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-5324","authenticated-orcid":false,"given":"Veikko","family":"Salomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-0979","authenticated-orcid":false,"given":"Pekka","family":"Jousilahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamari","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti J.","family":"Kangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Soininen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"W\u00fcrtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"36231_CR1","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLOS Med. 12, e1001779 (2015).","journal-title":"PLOS Med."},{"key":"36231_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"36231_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41588-021-00885-0","volume":"53","author":"JD Szustakowski","year":"2021","unstructured":"Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat. Genet. 53, 942\u2013948 (2021).","journal-title":"Nat. Genet."},{"key":"36231_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.12688\/wellcomeopenres.16171.2","volume":"5","author":"NE Allen","year":"2021","unstructured":"Allen, N. E. et al. Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. Wellcome Open Res. 5, 222 (2021).","journal-title":"Wellcome Open Res."},{"key":"36231_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41588-020-00757-z","volume":"53","author":"N Sinnott-Armstrong","year":"2021","unstructured":"Sinnott-Armstrong, N. et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat. Genet. 53, 185\u2013194 (2021).","journal-title":"Nat. Genet."},{"key":"36231_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219\u20131224 (2018).","journal-title":"Nat. Genet."},{"key":"36231_CR7","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"P W\u00fcrtz","year":"2017","unstructured":"W\u00fcrtz, P. et al. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am. J. Epidemiol. 186, 1084\u20131096 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"36231_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41591-021-01266-0","volume":"27","author":"M Pietzner","year":"2021","unstructured":"Pietzner, M. et al. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat. Med. 27, 471\u2013479 (2021).","journal-title":"Nat. Med."},{"key":"36231_CR9","doi-asserted-by":"publisher","first-page":"e63033","DOI":"10.7554\/eLife.63033","volume":"10","author":"H Julkunen","year":"2021","unstructured":"Julkunen, H., Cicho\u0144ska, A., Slagboom, P. E. & W\u00fcrtz, P. Nightingale Health UK Biobank Initiative. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. eLife 10, e63033 (2021).","journal-title":"eLife"},{"key":"36231_CR10","doi-asserted-by":"publisher","first-page":"e79348","DOI":"10.7554\/eLife.79348","volume":"11","author":"CJ Smith","year":"2022","unstructured":"Smith, C. J. et al. Integrative analysis of metabolite GWAS illuminates the molecular basis of pleiotropy and genetic correlation. eLife 11, e79348 (2022).","journal-title":"eLife"},{"key":"36231_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02399-w","volume":"20","author":"MC Borges","year":"2022","unstructured":"Borges, M. C. et al. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank participants. BMC Med. 20, 210 (2022).","journal-title":"BMC Med."},{"key":"36231_CR12","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. Longitudinal analysis of UK Biobank participants suggests age and APOE-dependent alterations of energy metabolism in development of dementia. medRxiv https:\/\/doi.org\/10.1101\/2022.02.25.22271530 (2022).","DOI":"10.1101\/2022.02.25.22271530"},{"key":"36231_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02354-9","volume":"20","author":"F Bragg","year":"2022","unstructured":"Bragg, F. et al. Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study. BMC Med. 20, 159 (2022).","journal-title":"BMC Med."},{"key":"36231_CR14","doi-asserted-by":"publisher","first-page":"e3001547","DOI":"10.1371\/journal.pbio.3001547","volume":"20","author":"TG Richardson","year":"2022","unstructured":"Richardson, T. G. et al. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation. PLOS Biol. 20, e3001547 (2022).","journal-title":"PLOS Biol."},{"key":"36231_CR15","doi-asserted-by":"publisher","unstructured":"Nag, A. et al. Assessing the contribution of rare-to-common protein-coding variants to circulating metabolic biomarker levels via 412,394 UK Biobank exome sequences. medRxiv https:\/\/doi.org\/10.1101\/2021.12.24.21268381 (2021).","DOI":"10.1101\/2021.12.24.21268381"},{"key":"36231_CR16","doi-asserted-by":"publisher","first-page":"100457","DOI":"10.1016\/j.lanepe.2022.100457","volume":"21","author":"JA Bell","year":"2022","unstructured":"Bell, J. A. et al. Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: a multivariable Mendelian randomization study. Lancet Reg. Health - Eur. 21, 100457 (2022).","journal-title":"Lancet Reg. Health - Eur."},{"key":"36231_CR17","doi-asserted-by":"crossref","unstructured":"Fang, S., Holmes, M. V., Gaunt, T. R., Smith, G. D. & Richardson, T. G. Constructing an atlas of associations between polygenic scores from across the human phenome and circulating metabolic biomarkers. eLife. 11, e73951 (2022).","DOI":"10.7554\/eLife.73951"},{"key":"36231_CR18","doi-asserted-by":"crossref","unstructured":"Ritchie, S. C. et al. Quality control and removal of technical variation of NMR metabolic biomarker data in ~120,000 UK Biobank participants. Sci Data. 10, 64 (2023).","DOI":"10.1038\/s41597-023-01949-y"},{"key":"36231_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen, P., Kangas, A. J., W\u00fcrtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 8, 192\u2013206 (2015).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"36231_CR20","doi-asserted-by":"publisher","first-page":"e021995","DOI":"10.1161\/JAHA.121.021995","volume":"10","author":"E Tikkanen","year":"2021","unstructured":"Tikkanen, E. et al. Metabolic biomarker discovery for risk of peripheral artery disease compared with coronary artery disease: lipoprotein and metabolite profiling of 31,657 individuals from 5 prospective cohorts. J. Am. Heart Assoc. 10, e021995 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"36231_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08936-1","volume":"10","author":"LBL Wittemans","year":"2019","unstructured":"Wittemans, L. B. L. et al. Assessing the causal association of glycine with risk of cardio-metabolic diseases. Nat. Commun. 10, 1060 (2019).","journal-title":"Nat. Commun."},{"key":"36231_CR22","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","volume":"71","author":"MV Holmes","year":"2018","unstructured":"Holmes, M. V. et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J. Am. Coll. Cardiol. 71, 620\u2013632 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"36231_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jacc.2015.12.060","volume":"67","author":"P W\u00fcrtz","year":"2016","unstructured":"W\u00fcrtz, P. et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J. Am. Coll. Cardiol. 67, 1200\u20131210 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"36231_CR24","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","volume":"138","author":"E Sliz","year":"2018","unstructured":"Sliz, E. et al. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation 138, 2499\u20132512 (2018).","journal-title":"Circulation"},{"key":"36231_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11311-9","volume":"10","author":"J Deelen","year":"2019","unstructured":"Deelen, J. et al. A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. Nat. Commun. 10, 3346 (2019).","journal-title":"Nat. Commun."},{"key":"36231_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cels.2015.09.007","volume":"1","author":"SC Ritchie","year":"2015","unstructured":"Ritchie, S. C. et al. The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. Cell Syst. 1, 293\u2013301 (2015).","journal-title":"Cell Syst."},{"key":"36231_CR27","doi-asserted-by":"publisher","first-page":"e002234","DOI":"10.1161\/CIRCGEN.118.002234","volume":"11","author":"J Kettunen","year":"2018","unstructured":"Kettunen, J. et al. Biomarker glycoprotein acetyls is associated with the risk of a wide spectrum of incident diseases and stratifies mortality risk in angiography patients. Circ. Genom. Precis. Med. 11, e002234 (2018).","journal-title":"Circ. Genom. Precis. Med."},{"key":"36231_CR28","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41591-022-01980-3","volume":"28","author":"T Buergel","year":"2022","unstructured":"Buergel, T. et al. Metabolomic profiles predict individual multidisease outcomes. Nat. Med. 28, 2309\u20132320 (2022).","journal-title":"Nat. Med."},{"key":"36231_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jalz.2018.01.003","volume":"14","author":"J Tynkkynen","year":"2018","unstructured":"Tynkkynen, J. et al. Association of branched\u2010chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer\u2019s disease: a prospective study in eight cohorts. Alzheimers Dement. 14, 723\u2013733 (2018).","journal-title":"Alzheimers Dement."},{"key":"36231_CR30","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/nm.3686","volume":"20","author":"JR Mayers","year":"2014","unstructured":"Mayers, J. R. et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20, 1193\u20131198 (2014).","journal-title":"Nat. Med."},{"key":"36231_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ije\/dym276","volume":"37","author":"P Elliott","year":"2008","unstructured":"Elliott, P. & Peakman, T. C. on behalf of UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37, 234\u2013244 (2008).","journal-title":"Int. J. Epidemiol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36231-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T13:12:56Z","timestamp":1675429976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-36231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36231"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-36231-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.J., M.T., H.K., K.N., V.M., J.N.-K., A.J.K., P.S., J.B., and P.W. are employees of Nightingale Health Plc, and hold shares or stock options in Nightingale Health Plc. A.C. is former employee of Nightingale Health Plc. V.S. has received an honorarium for consulting from Sanofi and has ongoing research collaboration with Bayer Ltd outside this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"604"}}